Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of capecitabine with chemotherapy in advanced or metastatic gastric cancer
2006-004512-43Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Mar 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in gastric cancer (GC), sponsored by Roche Farma, S.A. Primary endpoint: Incidence of hand-foot syndrome. Started Mar 2010; status: completed.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2006-004512-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004512-43.